The Board of Directors of Ranbaxy Laboratories Limited (Ranbaxy) at their meeting held today took on record the audited results for the year ended December 31, 2006 (Year 2006). The Board of Directors also took on record the consolidated audited results of Ranbaxy Laboratories Limited and its Subsidiaries for the year ended December 31, 2006 (Year 2006).

The Board of Directors has approved payment of the 2nd Interim Dividend of 120% i.e. Rs.6 per share of par value of Rs.5 each for the year ended December 31, 2006. Earlier in November 2006 an interim dividend of 50% i.e. Rs.2.50 per share was paid. This takes the total dividend for the year to 170% or Rs.8.50 per share. In view of this, no final dividend has been recommended by the Board.

Ranbaxy Laboratories Limited & Subsidiaries

For the year 2006, the Company recorded Consolidated Sales of Rs. 60,652 Mn [USD 1,339 Mn] (2005: Rs. 51,880 Mn, USD 1176 Mn), registering a growth of 17%. Profit before interest, depreciation, tax and amortization was at Rs. 9,390 Mn [USD 207 Mn] (2005: Rs. 3,727 Mn, USD 85 Mn), an increase of 152%. Profit before tax before exceptional items was at Rs 6,510 Mn [USD 144 Mn] (2005: Rs 1,611 Mn, USD 36 Mn), up 304%. Profit after tax was at Rs. 5,154 Mn [USD 114 Mn] (2005: Rs. 2,642 Mn, USD 60 Mn), recording an increase of 95%

Earnings per share on a fully diluted basis were Rs.13.17 (2005: Rs. 6.84).

Global Sales

For the year 2006, consolidated sales stood at USD 1339 Mn, an increase of 17%*. The sales growth was driven by North America and the BRICS markets which together accounted for 65% of total sales as against 61% in the corresponding period. These markets had combined sales of USD 869 Mn, recording an increase of 25%. The international business recorded sales of USD 1060 Mn, up 18% and contributed 79% to total sales.

*Excluding discontinued operations (Allied Businesses)

- End -

About Ranbaxy Laboratories

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. Ranbaxy’s continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. The Company’s foray into Novel Drug Delivery Systems has led to proprietary "platform technologies", resulting in a number of products under development. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 49 countries and manufacturing operations in 9 countries.

For more information, visit www.ranbaxy.com.